---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-044212"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:35:45.460083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arvinas presents positive Phase 1 data for ARV-102; biomarker modulation in CSF seen

## Summary
- ARV-102 well tolerated up to 200 mg single dose and 80 mg daily; no SAEs or discontinuations.
- Dose-dependent CSF exposure confirmed in healthy volunteers and Parkinson's patients.
- Daily doses ≥20 mg reduced PBMC LRRK2 by >90%; 200 mg dose in patients achieved 97% reduction.
- CSF proteomics showed decreases in lysosomal and neuroinflammatory microglial markers after 14 days.
- Arvinas plans to report multiple-dose Parkinson's data in 2026 and initiate Phase 1b PSP trial H1 2026.

## SEC filing metadata
- accession: 0001628280-25-044212
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/0001628280-25-044212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-20251005.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-044212
- JSON: https://secwatch.observer/filing/0001628280-25-044212.json
- Plain text: https://secwatch.observer/filing/0001628280-25-044212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.